reviewed april 2026|next review october 2026|88 physicians psi has verified|1167686 published studies
Thymalfasin (Thymosin Alpha-1 Synthetic)
Thymalfasin is the international nonproprietary name for synthetic thymosin alpha-1, marketed as Zadaxin and approved in 35+ countries for immune modulation, with the most extensive regulatory track record of any immune peptide globally.
Evidence landscape: 1167686 published studies
Published studies span viral hepatitis, cancer immunotherapy, and basic immunology. Extensive clinical data from approved use in 35+ countries.
- 12 Human
- 118 Animal
- 70 Reviews
- 1167486 Other research
Not FDA-approved in the United States. Approved in 35+ countries including China, Italy, and multiple Asian and European markets as Zadaxin for immune modulation in viral hepatitis and immunodeficiency.
Available by prescription in 35+ countries as Zadaxin. Not available through US pharmacies. The compound is identical to thymosin alpha-1. See PSI's thymosin alpha-1 page for the complete biological overview.
Thymalfasin is the pharmaceutical-grade synthetic form of thymosin alpha-1, a 28-amino acid naturally occurring (the body's own) thymic peptide. It bridges innate and adaptive immunity through TLR2/TLR9 activation. This page covers the pharmaceutical product specifically. Cross-reference: thymosin-alpha-1.
PSI Assessment
Thymalfasin (Zadaxin) has something no other immune peptide can claim: regulatory approval in more than 35 countries for immune modulation. It is identical to naturally occurring thymosin alpha-1, a 28-amino acid peptide that bridges innate and adaptive immunity through TLR2 and TLR9 activation on dendritic cells. Clinical evidence supports its use as adjunct therapy for viral hepatitis B and C, and it has been studied in cancer immunotherapy combinations. The compound is not FDA-approved in the United States, making it one of the most widely approved peptides internationally that remains unavailable through US regulatory channels.
Approved in 35+ countries as Zadaxin. Most extensive regulatory track record of any immune peptide. T-cell maturation through TLR2/TLR9. Not FDA-approved in the United States.
The mechanism is identical to thymosin alpha-1: TLR2 and TLR9 activation on dendritic cells and macrophages, promoting CD4+ and CD8+ T-cell maturation, NK cell activation, and interferon-alpha production. Thymalfasin bridges innate and adaptive immunity by activating antigen-presenting cells that then instruct the adaptive immune response. The pharmaceutical-grade synthetic form (Zadaxin) provides consistent purity and potency for clinical use across multiple indications.
What the evidence supports
Thymalfasin (Zadaxin) is approved in 35+ countries with the most extensive regulatory track record of any immune peptide globally. T-cell maturation enhancement through TLR2/TLR9 activation is well-characterized. Clinical efficacy as adjunct therapy for viral hepatitis B and C is supported by multiple controlled trials. Dendritic cell stimulation and bridging of innate and adaptive immunity are documented. Excellent safety profile from decades of clinical use in multiple countries.
What is not yet established
FDA approval in the United States. Whether immune enhancement benefits extend to healthy adults without existing immune deficiency or viral infection. Optimal use in cancer immunotherapy combinations. Whether thymalfasin provides meaningful benefit as monotherapy versus adjunctive use.
Research Evidence
The findings below cover the hepatitis adjunct therapy evidence, the cancer immunotherapy data, and the immunomodulatory mechanism.
Evidence by condition
Evidence dimensions across hepatitis, cancer adjunct therapy, and immunodeficiency. Hepatitis has the deepest clinical evidence supporting regulatory approval.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| HBV/HCV Adjunct Therapy | ||||
| Cancer Immunotherapy Adjunct | ||||
| Immunodeficiency |
Multiple controlled trials demonstrate that thymalfasin enhances viral clearance rates when combined with interferon therapy for hepatitis B and C. This evidence base supports regulatory approval in 35+ countries.
The hepatitis adjunct indication has the strongest clinical evidence. Thymalfasin is used as combination therapy rather than monotherapy for viral hepatitis.
Clinical studies in cancer patients show that thymalfasin enhances immune recovery during chemotherapy and improves T-cell and NK cell activation when used as an immunoadjuvant.
The cancer immunotherapy adjunct evidence spans hepatocellular carcinoma, melanoma, and lung cancer. The combination study design makes it difficult to isolate thymalfasin's specific contribution.
The TLR2/TLR9 mechanism of immune activation is well-characterized. Thymalfasin activates dendritic cells to promote T-cell maturation and bridge innate and adaptive immunity.
The mechanism explains the broad immunomodulatory effects observed across disease populations. Whether these effects are clinically meaningful in healthy adults is the open question.
12 Human|118 Animal|70 Reviews
View all 1167686 indexed studiesHow Thymalfasin (Thymosin Alpha-1 Synthetic) Works
Thymalfasin is synthetic thymosin alpha-1, a 28-amino acid naturally occurring (the body's own) thymic peptide. It activates TLR2/TLR9 on dendritic cells and macrophages, promoting T-cell maturation, NK cell activation, and bridging innate and adaptive immunity.
Thymalfasin (Zadaxin) is identical to naturally occurring thymosin alpha-1. It enhances immune function by stimulating T-cell maturation, activating dendritic cells, and bridging innate and adaptive immunity. The pharmaceutical-grade synthetic form provides consistent purity and potency for clinical use.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Thymalfasin is synthetic thymosin alpha-1 (28 amino acids, N-terminally acetylated). It activates TLR2 and TLR9 on dendritic cells and macrophages, promoting T-cell maturation (CD4+ and CD8+), bridging innate and adaptive immunity, and enhancing NK cell activity. Approved in 35+ countries as Zadaxin for immune modulation.
What is Thymalfasin (Thymosin Alpha-1 Synthetic) being studied for?
Researchers are studying Thymalfasin (Thymosin Alpha-1 Synthetic) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymalfasin (Thymosin Alpha-1 Synthetic) overall. This means a compound can have human studies for one condition but only animal data for another.
HBV/HCV Adjunct Therapy
·Human TrialsApproved in 35+ countries as adjunct therapy for viral hepatitis B and C. Multiple controlled trials demonstrate enhanced viral clearance when combined with interferon therapy.
Limitations: Not FDA-approved in the United States. Primarily used as adjunctive rather than monotherapy. Whether thymalfasin is needed in the era of direct-acting antivirals for HCV is being reassessed.
Cancer Immunotherapy Adjunct
·Animal StudiesClinical studies show immune enhancement when combined with chemotherapy. T-cell and NK cell activation improvement documented in cancer patients receiving chemotherapy.
Limitations: Not approved for cancer indications. Combination study designs make it difficult to isolate thymalfasin's specific contribution. No Phase III cancer trial has been completed.
Immunodeficiency
·Animal StudiesUsed clinically in multiple countries for broad immune reconstitution in immunocompromised patients. T-cell maturation and dendritic cell activation provide multi-pathway immune support.
Limitations: Evidence is strongest in disease populations. Whether immune enhancement extends to healthy adults seeking immune optimization is not established.
Safety and Regulatory Status
FDA Status: Not FDA-approved in the United States. Approved in 35+ countries as Zadaxin for immune modulation.
Availability: Available by prescription in 35+ countries. Not available through US pharmacies. Identical to thymosin alpha-1. See PSI's thymosin alpha-1 page.
Class context: Excellent safety profile from decades of clinical use in multiple countries. Side effects are minimal and the compound is well tolerated. The molecule is identical to a naturally occurring (the body's own) thymic peptide.
Thymalfasin has an excellent safety profile from decades of clinical use in 35+ countries. Minimal side effects are reported. The compound is identical to a naturally occurring (the body's own) peptide.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Thymalfasin (Thymosin Alpha-1 Synthetic) discussion.
Comparison and Related Research
Thymalfasin is compared with the parent compound thymosin alpha-1 and other immune peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational study identifying the SNARE protein complex, including SNAP-25, as the core machinery for synaptic vesicle fusion and neurotransmitter release. SNAP-25 was shown to form a four-helix bundle with syntaxin and VAMP/synaptobrevin, providing the molecular force that drives membrane fusion at the synapse.Sollner T et al., 1993 in Nature. View on PubMed
- 2.Review linking SNAP-25 dysfunction to attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and other neuropsychiatric conditions. Genetic studies identified SNAP-25 polymorphisms associated with ADHD risk, and altered SNAP-25 expression was found in postmortem brain tissue from patients with schizophrenia, establishing the protein as a molecular bridge between synaptic function and psychiatric disease.Bhatt DK et al., 2003 in Neuroscience. View on PubMed
- 3.Genetic association study identifying single nucleotide polymorphisms in the SNAP-25 gene that were significantly associated with ADHD in a family-based cohort. The T1065G and T1069C variants in the 3' untranslated region showed transmission disequilibrium, providing the first direct genetic evidence linking SNAP-25 to ADHD susceptibility.Barr CL et al., 2000 in Mol Psychiatry. View on PubMed
- 4.Postmortem brain study measuring SNAP-25 splice variant levels in patients with schizophrenia compared to matched controls. Reduced SNAP-25a expression was found in the hippocampus and prefrontal cortex of schizophrenia patients, with the ratio of SNAP-25a to SNAP-25b significantly altered, linking specific isoform changes to the disease.Thompson PM et al., 2003 in Biol Psychiatry. View on PubMed
- 5.Study examining SNAP-25 variants in autism spectrum disorder and their effects on cognitive function. Specific polymorphisms were associated with differences in working memory and executive function, and the research explored how modulating SNAP-25-dependent neurotransmitter release might offer therapeutic approaches for cognitive symptoms in autism.Braida D et al., 2015 in Genes Brain Behav. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.